Hunan Er-Kang Pharmaceutical Co., Ltd (SHE:300267)
China
· Delayed Price · Currency is CNY 4.080
-0.010 (-0.25%)
Mar 10, 2026, 3:04 PM CST
SHE:300267 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Operating Revenue | 1,280 | 1,128 | 1,766 | 1,860 | 2,229 | 2,374 | Upgrade
|
| Other Revenue | 11.38 | 11.38 | 16.76 | 10.63 | 6.43 | 7.84 | Upgrade
|
| Revenue | 1,292 | 1,140 | 1,783 | 1,871 | 2,235 | 2,382 | Upgrade
|
| Revenue Growth (YoY) | 8.36% | -36.09% | -4.67% | -16.32% | -6.17% | -13.19% | Upgrade
|
| Cost of Revenue | 990.77 | 849.75 | 1,501 | 1,460 | 1,916 | 1,859 | Upgrade
|
| Gross Profit | 300.98 | 289.86 | 281.73 | 410.79 | 319.44 | 523.46 | Upgrade
|
| Selling, General & Admin | 274.92 | 324.12 | 401.33 | 352.89 | 417.49 | 365.39 | Upgrade
|
| Research & Development | 41.3 | 45.17 | 57.44 | 48.15 | 49.02 | 48.07 | Upgrade
|
| Other Operating Expenses | 13.75 | 9.36 | 12.37 | 12.86 | 14.96 | 12.94 | Upgrade
|
| Operating Expenses | 328.15 | 380.04 | 464.81 | 421.45 | 469.93 | 447.13 | Upgrade
|
| Operating Income | -27.17 | -90.18 | -183.08 | -10.65 | -150.49 | 76.33 | Upgrade
|
| Interest Expense | -8.92 | -8.68 | -6.66 | -5.84 | -9.29 | -15.35 | Upgrade
|
| Interest & Investment Income | 7.48 | 4.73 | 9.59 | 7.17 | 20.65 | 129.45 | Upgrade
|
| Currency Exchange Gain (Loss) | -5.68 | -5.68 | 3.72 | -8.44 | 1.98 | -0.9 | Upgrade
|
| Other Non Operating Income (Expenses) | 8.55 | 10.79 | -31.86 | -0.57 | -5.42 | 0.63 | Upgrade
|
| EBT Excluding Unusual Items | -25.74 | -89.01 | -208.3 | -18.34 | -142.57 | 190.16 | Upgrade
|
| Impairment of Goodwill | - | - | -8.01 | - | -19.83 | - | Upgrade
|
| Gain (Loss) on Sale of Investments | -60.16 | -55.41 | -14.54 | 14.12 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.35 | 0.2 | 8.8 | 0.05 | 0.23 | 0.22 | Upgrade
|
| Asset Writedown | -238.12 | -237.41 | -12.91 | -0 | -683.35 | -2.55 | Upgrade
|
| Legal Settlements | -12.9 | -12.9 | - | - | -20.65 | -15.39 | Upgrade
|
| Other Unusual Items | 2.9 | 6.42 | 36.01 | 21.52 | 20.38 | 29.1 | Upgrade
|
| Pretax Income | -333.67 | -388.12 | -198.93 | 17.35 | -845.78 | 201.53 | Upgrade
|
| Income Tax Expense | 4.96 | 4.51 | 22.92 | -19.72 | -47.54 | 20.17 | Upgrade
|
| Earnings From Continuing Operations | -338.63 | -392.63 | -221.85 | 37.08 | -798.23 | 181.36 | Upgrade
|
| Minority Interest in Earnings | 30.3 | 19.26 | 26.53 | 8.87 | 7.03 | 10.95 | Upgrade
|
| Net Income | -308.33 | -373.37 | -195.32 | 45.94 | -791.2 | 192.31 | Upgrade
|
| Net Income to Common | -308.33 | -373.37 | -195.32 | 45.94 | -791.2 | 192.31 | Upgrade
|
| Net Income Growth | - | - | - | - | - | 21.13% | Upgrade
|
| Shares Outstanding (Basic) | 2,056 | 2,063 | 2,063 | 2,060 | 2,063 | 2,063 | Upgrade
|
| Shares Outstanding (Diluted) | 2,056 | 2,063 | 2,063 | 2,060 | 2,063 | 2,063 | Upgrade
|
| Shares Change (YoY) | -0.50% | 0.01% | 0.11% | -0.11% | -0.04% | 0.08% | Upgrade
|
| EPS (Basic) | -0.15 | -0.18 | -0.09 | 0.02 | -0.38 | 0.09 | Upgrade
|
| EPS (Diluted) | -0.15 | -0.18 | -0.09 | 0.02 | -0.38 | 0.09 | Upgrade
|
| EPS Growth | - | - | - | - | - | 21.04% | Upgrade
|
| Free Cash Flow | 163.49 | -28.91 | -89.77 | 107.53 | -256.65 | -482.4 | Upgrade
|
| Free Cash Flow Per Share | 0.08 | -0.01 | -0.04 | 0.05 | -0.12 | -0.23 | Upgrade
|
| Dividend Per Share | - | - | - | 0.030 | - | 0.050 | Upgrade
|
| Dividend Growth | - | - | - | - | - | 400.00% | Upgrade
|
| Gross Margin | 23.30% | 25.44% | 15.80% | 21.96% | 14.29% | 21.97% | Upgrade
|
| Operating Margin | -2.10% | -7.91% | -10.27% | -0.57% | -6.73% | 3.20% | Upgrade
|
| Profit Margin | -23.87% | -32.76% | -10.95% | 2.46% | -35.40% | 8.07% | Upgrade
|
| Free Cash Flow Margin | 12.66% | -2.54% | -5.03% | 5.75% | -11.48% | -20.25% | Upgrade
|
| EBITDA | 158.5 | 101.32 | 16.2 | 158 | 41.09 | 267.68 | Upgrade
|
| EBITDA Margin | 12.27% | 8.89% | 0.91% | 8.45% | 1.84% | 11.24% | Upgrade
|
| D&A For EBITDA | 185.67 | 191.5 | 199.27 | 168.66 | 191.59 | 191.36 | Upgrade
|
| EBIT | -27.17 | -90.18 | -183.08 | -10.65 | -150.49 | 76.33 | Upgrade
|
| EBIT Margin | -2.10% | -7.91% | -10.27% | -0.57% | -6.73% | 3.20% | Upgrade
|
| Effective Tax Rate | - | - | - | - | - | 10.01% | Upgrade
|
| Revenue as Reported | 1,292 | 1,140 | 1,783 | 1,871 | 2,235 | 2,382 | Upgrade
|
| Advertising Expenses | - | 0.56 | 0.88 | 0.34 | 2.5 | 0.92 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.